We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Randomized trial compares clinical outcomes between nivolumab and bevacizumab in recurrent glioblastoma, highlighting therapeutic alternatives for progressive brain tumors.
ClinicalTrials.gov Identifier: NCT02017717.
No takes yet. Share an insight, caveat, or question.
Reardon et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: